Last reviewed · How we verify
NCT07135388: REU-SA
Treatment of Rheumatologic Patients With Sarcopenia
NA trial testing Food for special medical purposes in Rheumatic Diseases in 15 participants. Completed in 31 December 2024.
30 December 2024
Quick facts
| Lead sponsor | University of Bari |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 31 January 2021 |
| Primary completion | 30 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Food for special medical purposes
Conditions studied
- Rheumatic Diseases — all drugs for Rheumatic Diseases →
Sponsor
University of Bari
Who can join
Adults 18 to 65, any sex, with Rheumatic Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sarcopenia is defined as a pathological condition related to muscle strength and muscle mass reduction. It is caused by ageing (primary sarcopenia) and diseases associated with systemic inflammation (secondary sarcopenia). Systemic inflammation in rheumatological diseases often leads to physical inactivity, which is the main predictor of sarcopenia in this pathological condition. In these patients, the treatment of sarcopenia must necessarily include an appropriate nutritional approach, and the addition of oral supplements should be considered a complementary approach.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07135388
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rheumatic Diseases
Currently open trials in the same condition.
- NCT07490041 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refr · EARLY_PHASE1 · recruiting
- NCT07350395 — Exploring and Measuring the Impact of Steroids in Children and Young People · recruiting
- NCT07278609 — The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions · recruiting
- NCT07148414 — A Study of SPY072 in Rheumatic Disease · Phase 2 · recruiting
- NCT06400628 — Effectiveness of Chronic Self-management Education on Behavioral and Clinical Outcomes · NA · recruiting
Other University of Bari trials
Trials by the same sponsor.
- NCT06854133 — Factors of Effectiveness in Italian Forensic Treatment · not yet recruiting
- NCT07125625 — Probiotic Mixture (L. Rhamnosus GG and L. Plantarum 299V) In Pediatric Irritable Bowel Syndrome · NA · not yet recruiting
- NCT07036627 — Intestinal Microbiota After PPI Treatment · not yet recruiting
- NCT07050693 — Efficacy of a 2'-Fucosylactose-based Food Supplement on the Prevention of Respiratory and Gastrointestinal Infections. · NA · recruiting
- NCT06719999 — PRIMA Project- Box for Heath and Tradition (B4HT) · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07135388 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Bari
- Last refreshed: 29 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07135388.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing